Equities

Qingdao NovelBeam Technology Co Ltd

688677:SHH

Qingdao NovelBeam Technology Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (CNY)37.50
  • Today's Change-1.64 / -4.19%
  • Shares traded1.16m
  • 1 Year change-36.47%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments631636723
Total Receivables, Net9913769
Total Inventory17113866
Prepaid expenses3.927.402.70
Other current assets, total0.150.130.27
Total current assets905918861
Property, plant & equipment, net414403280
Goodwill, net------
Intangibles, net313131
Long term investments24300.59
Note receivable - long term------
Other long term assets------
Total assets1,3951,3941,182
LIABILITIES
Accounts payable406029
Accrued expenses191914
Notes payable/short-term debt000
Current portion long-term debt/capital leases2.29173.46
Other current liabilities, total257122
Total current liabilities8516768
Total long term debt3.641.9119
Total debt5.931922
Deferred income tax0.04----
Minority interest0.153.243.74
Other liabilities, total131.87--
Total liabilities10217491
SHAREHOLDERS EQUITY
Common stock1228787
Additional paid-in capital656692681
Retained earnings (accumulated deficit)548472325
Treasury stock - common(34)(30)--
Unrealized gain (loss)------
Other equity, total1.42(0.79)(1.97)
Total equity1,2931,2191,091
Total liabilities & shareholders' equity1,3951,3941,182
Total common shares outstanding121121122
Treasury shares - common primary issue0.680.470
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.